Researchers from the University of Virginia in Charlottesville have discovered a type of gut bacteria that could prove effective where other types of helpful bacteria have failed in the fight against ...

As Clostridium difficile creates a significant economic and morbidity burden for hospitals, researchers with Cleveland Clinic and the University of Texas School of Public Health in Houston sought to ...

There are inherent risks in biotech investing. A decade’s worth and often hundreds of millions of dollars in R&D, along with binary risks of failed clinical trials or regulatory approval. Above and ...

According to the Centers for Disease Control and Prevention, 47 million courses (PDF) of antibiotics were prescribed for infections that didn’t need them in 2018. And taking antibiotics is “like ...

C. diff is a horrible disease that can cause significant morbidity. It can and often does recur and kills around 30,000 Americans every year. We have made progress in prevention and treatment, but ...

The antibiotic vancomycin, recommended as first-line treatment for infection caused by the deadly superbug C. difficile (C. diff), may not be living up to its promise, according to new research. The ...

MALIBU, Calif., Nov. 13, 2019 /PRNewswire/ -- Several doctors spoke before the FDA in Washington D.C. on November 4, advocating for C.diff treatment improvements. Among those in attendance were ...

Paul Feuerstadt, MD, and Louis Korman, MD, spoke with Becker’s about how a study published in The New England Journal of Medicine could change how the gastroenterology industry treats Clostridioides ...

Fecal microbiota transplantation has become one of the most effective treatments for recurrent Clostridioides difficile infections, but its long-term role in gastroenterology may hinge on moving ...

In vitro, treatment with UDCA significantly decreased C. diff spore germination, growth and toxin activity. In the mouse model, pre-treatment with UDCA had some effect on bacterial growth, but the ...

Trillions of bacteria, viruses and other tiny organisms — called “microbes” — live inside our bodies and make up a community known as the microbiome. The diversity of microbes is like a rainforest in ...

LONDON--(BUSINESS WIRE)--The global clostridium difficile treatment market size is expected to grow by USD 159.87 million as per Technavio. This marks a significant market growth compared to the 2019 ...